BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32833283)

  • 1. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications.
    Rey JR; Caro-Codón J; Rosillo SO; Iniesta ÁM; Castrejón-Castrejón S; Marco-Clement I; Martín-Polo L; Merino-Argos C; Rodríguez-Sotelo L; García-Veas JM; Martínez-Marín LA; Martínez-Cossiani M; Buño A; Gonzalez-Valle L; Herrero A; López-Sendón JL; Merino JL;
    Eur J Heart Fail; 2020 Dec; 22(12):2205-2215. PubMed ID: 32833283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
    Stienen S; Salah K; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Tijssen JP; Pinto YM; Kok WE
    JACC Heart Fail; 2016 Sep; 4(9):736-45. PubMed ID: 27395353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
    Núñez J; Llàcer P; Bertomeu-González V; Bosch MJ; Merlos P; García-Blas S; Montagud V; Bodí V; Bertomeu-Martínez V; Pedrosa V; Mendizábal A; Cordero A; Gallego J; Palau P; Miñana G; Santas E; Morell S; Llàcer A; Chorro FJ; Sanchis J; Fácila L;
    JACC Heart Fail; 2016 Nov; 4(11):833-843. PubMed ID: 27522630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
    Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
    Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
    JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
    JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
    Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
    Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
    J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Long-Term Mortality and Frequent Re-Hospitalization in Patients with Acute Decompensated Heart Failure and Kidney Dysfunction Treated with Renin-Angiotensin System Blockers.
    Baydemir C; Ural D; Karaüzüm K; Balci S; Argan O; Karaüzüm I; Kozdağ G; Ağır AA
    Med Sci Monit; 2017 Jul; 23():3335-3344. PubMed ID: 28690311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Canepa M; Straburzynska-Migaj E; Drozdz J; Fernandez-Vivancos C; Pinilla JMG; Nyolczas N; Temporelli PL; Mebazaa A; Lainscak M; Laroche C; Maggioni AP; Piepoli MF; Coats AJS; Ferrari R; Tavazzi L;
    Eur J Heart Fail; 2018 Jan; 20(1):100-110. PubMed ID: 28949063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
    Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
    J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure.
    Ahn MS; Yoo BS; Yoon J; Lee SH; Kim JY; Ahn SG; Youn YJ; Lee JW; Son JW; Kim HS; Kang DR; Lee SE; Cho HJ; Lee HY; Jeon ES; Kang SM; Choi DJ; Cho MC
    J Korean Med Sci; 2019 May; 34(17):e133. PubMed ID: 31050223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
    Felker GM; Ahmad T; Anstrom KJ; Adams KF; Cooper LS; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Leifer ES; Mark DB; Desvigne-Nickens P; Paynter G; Piña IL; Whellan DJ; O'Connor CM
    JACC Heart Fail; 2014 Oct; 2(5):457-65. PubMed ID: 25194287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
    Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
    J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.
    Samsky MD; Lin L; Greene SJ; Lippmann SJ; Peterson PN; Heidenreich PA; Laskey WK; Yancy CW; Greiner MA; Hardy NC; Kavati A; Park S; Mentz RJ; Fonarow GC; O'Brien EC
    JAMA Cardiol; 2020 Mar; 5(3):292-299. PubMed ID: 31734700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe.
    Fröhlich H; Rosenfeld N; Täger T; Goode K; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Clark AL; Frankenstein L; Grundtvig M
    Heart; 2019 Aug; 105(16):1252-1259. PubMed ID: 30792238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease.
    Cutshall BT; Duhart BT; Saikumar J; Samarin M; Hutchison L; Hudson JQ
    Am J Med Sci; 2018 Mar; 355(3):247-251. PubMed ID: 29549927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.